Sana Biotechnology.
biotechnology company
- Reports this week
- 1
- Active events
- 0
- Connections
- 39
What's happening
One to three months ago
-
Bank of America decreased its target price for Sana Biotechnology while Royal Bank of Canada increased its stock holdings.Some support1 report
-
Comparative analysis of market performance and risk factors between Sana Biotechnology and Endonovo Therapeutics.Some support1 report
-
Sana Biotechnology delivered encouraging six-month data on its allogeneic CAR-T platform for Type 1 diabetes.Some support2 reports
-
MarketBeat aggregated consensus rating data for Sana Biotechnology.Some support3 reports
Gone quiet
No new reports in 90+ days-
Sana Biotechnology benefits from Trump-era tariffs and onshoring trends, with Morgan Stanley analyst coverage starting on August 1, 2025.Some support2 reports
-
Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.Speculative1 report
-
Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.Some support1 report2 developments inside
-
Per-Ola Carlsson is appointed as the study principal investigator for Sana Biotechnology's ongoing treatments.Speculative2 reports
-
Sana Biotechnology reported financial results and received FDA feedback on its IND filing.Some support1 report1 development inside
-
An offering was filed with and declared effective by the SEC on August 21, 2025, with Morgan Stanley and TD Cowen serving as joint book-running managers for Sana Biotechnology.Some support3 reports
-
Citizens JMP reiterated a Buy rating on Sana Biotechnology on August 26, 2025.Some support1 report
-
Sana Biotechnology has established operations in Seattle, Washington.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Sana Biotechnology this week
News at the entities that move Sana Biotechnology most-
FDA StructuralBMD is listed on Nasdaq and received positive feedback from the FDA regarding its Phase 3 drug protocol.Moves Sana Biotechnology
-
Bank of America TransactionalSamsung and SK Hynix are upgrading Chinese memory facilities for AI, while Bank of America expects increased shareholder returns.Moves Sana Biotechnology
-
Nasdaq StructuralLightWave Acquisition Corp. has been listed on Nasdaq and is now subject to SEC tracking of institutional trading.Moves Sana Biotechnology
-
Morgan Stanley TransactionalInsider sold shares of CDW stock; Citigroup raised price target on CDW; Morgan Stanley lifted price target on CDW.Moves Sana Biotechnology
-
TD Cowen TransactionalGoldman Sachs, TD Cowen, and Barclays cited valuation and growth concerns, leading to downgrades on July 25, 2026.Moves Sana Biotechnology
-
Mayo Clinic OperationalRuchi Gupta, a statistical programmer at Mayo Clinic, has lived in Rochester for 25 years and discusses local issues.Moves Sana Biotechnology
Connections
The 12 strongest of 39, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Sana Biotechnology's operational viability and progress are dependent on regulatory approval and feedback from the FDA.
-
American Diabetes Association Operational
Sana Biotechnology presents clinical data and results at American Diabetes Association meetings.
-
Bank of America Transactional
Bank of America has lowered its price target for Sana Biotechnology.
-
GMP Structural
Sana Biotechnology is utilizing GMP's Master Cell Bank services to advance its product development.
-
Morgan Stanley Transactional
Morgan Stanley facilitated a capital raise for Sana Biotechnology by acting as a joint book-running manager and providing analyst coverage.
-
TD Cowen Transactional
TD Cowen served as a joint book-running manager for Sana Biotechnology during a financial event.
-
Sana Biotechnology is scheduled to present its UP421 clinical data at the annual symposium hosted by the European Association for the Study of Diabetes.
-
Mayo Clinic Operational
Sana Biotechnology and Mayo Clinic are engaged in a strategic collaboration focused on improving care for type 1 diabetes.
Show all 12 connections
-
Nasdaq Structural
Sana Biotechnology is formally listed on the Nasdaq exchange.
-
Royal Bank of Canada Transactional
The relationship is evidenced by Royal Bank of Canada increasing its stock holdings in Sana Biotechnology.
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data and tracks Sana Biotechnology's market performance.
-
Seattle Shared context
Sana Biotechnology is consistently reported to be based in and operate within Seattle.
History
Events by the month they beganAugust 2026
2 eventsJuly 2026
1 eventJune 2026
9 events- Sana Biotechnology delivered encouraging six-month data on its allogeneic CAR-T platform for Type 1 diabetes.
- Sana Biotechnology benefits from Trump-era tariffs and onshoring trends, with Morgan Stanley analyst coverage starting on August 1, 2025.
- Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.
- Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.
- Per-Ola Carlsson is appointed as the study principal investigator for Sana Biotechnology's ongoing treatments.
- Sana Biotechnology reported financial results and received FDA feedback on its IND filing.
- An offering was filed with and declared effective by the SEC on August 21, 2025, with Morgan Stanley and TD Cowen serving as joint book-running managers for Sana Biotechnology.
- Citizens JMP reiterated a Buy rating on Sana Biotechnology on August 26, 2025.
- Sana Biotechnology has established operations in Seattle, Washington.